{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Protein Tyrosine Kinase/PTK > RebastinibCAS：1020172-07-9
Molecular Formula：C30H28FN7O3
Molecular Weight：553.59
Storage：Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 1020172-07-9 |
| Name | Rebastinib |
| Molecular Formula | C30H28FN7O3 |
| Molecular Weight | 553.59 |
| Solubility | Soluble in DMSO |
| Purity | ≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD19443646 |
| SMILES | CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5 |
| Target Point | Bcr-Abl |
| Passage | Protein Tyrosine Kinase/RTK |
| Background | Rebastinib is a Bcr-Abl inhibitor. |
| Biological Activity | Rebastinib (DCC-2036) 是一种 Bcr-Abl 抑制剂抑制剂，作用于 Abl1WT 和 Abl1T315I，IC50 分别为 0.8 nM 和 4 nM，也抑制SRC，KDR，FLT3 和 Tie-2，低活性作用于c-Kit。[1] |
| Data Literature Source | [1]. Chan WW，et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase，including the gatekeeper T315I mutant，by the switch-control inhibitor DCC-2036. Cancer Cell. 2011，19(4)，556-568 |
| Unit | Bottle |
| Specification | 5mg 10mg 50mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
